VIVUS ANNOUNCES RESULTS OF EVAMIST TRIAL

A A

Vivus has announced positive results from a pivotal Phase III clinical trial of Evamist. The investigational estradiol metered dose transdermal spray is being developed for the treatment of vasomotor symptoms associated with menopause.

The study showed a statistically significant reduction in the number and severity of moderate and severe hot flashes for all three doses tested. Evamist is a novel, once a day proprietary, first-in-class, transdermal spray that delivers estradiol, a naturally occurring estrogen, for the treatment of hot flashes in women. Evamist is a small, hand-held spray that is designed to provide an easy and convenient means to deliver a preset dose of estradiol via the skin.